T. Rowe Price Associates
MTNB icon

T. Rowe Price Associates’s Matinas BioPharma MTNB Stock Holding History

T. Rowe Price Associates’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-226
Closed -$221K – 3024
2021
Q3 		$221K Hold
226
– – ﹤0.01% 2687
2021
Q2 		$132K Hold
226
– – ﹤0.01% 2802
2021
Q1 		$178K Buy
+226
New +$227K ﹤0.01% 2717

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $67.3M AUM 9.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

T. Rowe Price Associates's MTNB Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Matinas BioPharma (MTNB) in Q4 2021, closing a stake of 226 shares — an estimated $221K sold.

T. Rowe Price Associates first reported a position in MTNB in Q1 2021 and held it in 3 quarters. The position peaked at $221K in Q3 2021. 64 funds tracked by Wall St. Rank hold MTNB as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Matinas BioPharma position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 226 Matinas BioPharma shares in Q4 2021, an estimated $221K.
  • T. Rowe Price Associates first reported a position in Matinas BioPharma in Q1 2021 and held it in 3 quarters.
  • T. Rowe Price Associates's Matinas BioPharma position peaked at $221K in Q3 2021.
  • 64 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.